Evidence map›Paper›PMID 42026400›Full record

ArticleEJNMMI reports2026

Uptake of

Xiaodan Xu, Guanyun Wang, Xiaojun Zhang, Ruimin Wang, Guangyu Ma

Abstract read
In one paragraph

Article in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaodan XuDepartment of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Guanyun WangDepartment of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Xiaojun ZhangDepartment of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Ruimin WangDepartment of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Guangyu MaDepartment of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China. mgy301@163.com.ORCID http://orcid.org/0000-0003-1381-9341

Funding

National Clinical Key Specialty Construciong of Chinese People's Liberation Army 5156Z6E
6 · The paper itself

Abstract

Gastrointestinal stromal tumors (GISTs) are rare stromal neoplasms that predominantly arise in the gastrointestinal tract. 18F-AlF-NOTA-octreotide (18F-OC) is a novel molecularly targeted probe that specifically binds to tumors expressing somatostatin receptors. A 45-year-old male patient underwent 18F-OC PET/CT due to clinical suspicion of a pancreatic neuroendocrine tumor. Imaging revealed a mass with increased 18F-OC uptake inferior to the pancreatic head. The patient subsequently underwent surgical resection, and histopathological assessment confirmed a low-risk gastrointestinal stromal tumor.

Indexed as

18F-AlF-NOTA-octreotideGastrointestinal stromal tumorsPET/CT

Identifiers

PMID42026400
PMCPMC13106097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.